This report describes the use of a recombinant murine retrovirus encoding I8-galactosidase (PLJ I-gal retrovirus) to study the antiretroviral activity of zidovudine (AZT) and other nucleoside analogs. The PLJ n-gal virus permits the rapid and unequivocal identification of individual virus-infected cells arising from a single cycle of viral replication. With this model system, AZT is shown to completely and irreversibly prevent retrovirus infection of proliferating cell lines as measured by a lack of reporter gene expression. On the other hand, AZT is less effective in protecting growth-arrested cells from retroviral infection. Recombinant retroviruses such as the PLJ P-gal virus are potentially useful reagents for the identification and characterization of antiretroviral compounds.
Zidovudine (AZT) and other 2',3'-dideoxynucleosides, (ddNs), including dideoxyinosine (ddl) and dideoxycytosine (ddC), are potent inhibitors of retroviral replication (1, 3, 10-12, 16, 20) . These nucleoside analogs must be phosphorylated by cellular enzymes to the 5'-triphosphate form (ddNTP) to be active. Two antiretroviral mechanisms of action have been proposed for ddNTPs: (i) competitive inhibition of normal substrate (dNTP) binding to the retroviral reverse transcriptase and (ii) incorporation of ddNTPs (in the form of ddN-monophosphates) into retroviral DNA, resulting in DNA chain termination (1, 3, (10) (11) (12) 16 ). It is not known, however, which of these mechanisms is more important or whether either of these actions alone is sufficient to permanently block retroviral reverse transcription. In addition, other characteristics of ddNs, such as the influence of the host cell cycle on their antiretroviral activity, need to be described.
To address these questions, we have used a recombinant retrovirus (PLJ p-gal virus) that allows the rapid identification and quantitation of virus-infected cells. The Cells expressing the PLJ p-gal virus were detected either by staining with 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X-Gal) 48 h after infection or by clonal selection in the presence of G418 for 10 days. Uninfected control cells did not show any background staining with X-Gal or colony formation in the presence of G418. Figure 1 shows the concentration inhibition effect of AZT on PLJ p-gal virus infection. A 50% reduction in the number of p-galactosidasepositive cells was produced by -0.04 p.M AZT. Complete inhibition of infection as assessed by P-galactosidase expression was observed at 0.5 ,uM AZT ( Fig. 1 and 2 ). The reproducibility of this system is highlighted by the virtually identical results obtained when stable retrovirus expression was assessed by colony formation in the presence of G418 (Fig. 1) . AZT had no effect on cell viability or growth at concentrations of <1.0 p.M (data not shown).
To determine whether retroviral inhibition by AZT was reversible, experiments in which AZT treatment was stopped at increasing intervals after infection were performed. Cells were examined for evidence of delayed expression of the P-galactosidase marker gene over a 15-day period after infection. The PLJ f-gal virus was also used to assess the activity of other antiretroviral compounds. Figure 3 shows concentration inhibition curves for the nucleoside analogs ddl, ddC, and 2',3'-dideoxy-didehydrothymidine (d4T) and for the PP1 analog phosphonoformic acid (PFA). Complete inhibition of retroviral expression was observed at 0.5 ,uM d4T, 25 ,uM ddl, and 37.5 ,uM ddC. Three independent experiments failed to demonstrate PFA inhibition of retroviral infection of NIH 3T3 cells at drug concentrations that were not cytotoxic (<2,000 ,uM). The preparation of PFA used in our experiments inhibited human immunodeficiency virus type 1 (IIIB) replication in H9 and HeLa CD4 cells, indicating that active drug was used in our experiments. Other investigators studying the inhibition of reverse transcriptases by PFA have shown that the degree of inhibition is highly dependent on the type of retrovirus as well as on the nature of the primer and template used in the assay (7, 13, 19). For example, 50% inhibition of avian myeloblastosis virus reverse transcriptase activity occurs at 10 ,uM PFA when poly(rA) oligo(dT) is used as a template, but much higher drug concentrations are required to inhibit endogenous avian myeloblastosis virus reverse transcriptase activity (70% inhibition at 500 ,uM PFA) (19). By using poly(rC) oligo(dG) as a template, it was determined that Moloney murine leukemia virus reverse transcriptase is relatively insensitive to PFA (50% inhibition at 250 puM PFA) (7). Our experiments confirm this relative insensitivity and provide complementary information about the antiviral effects of PFA on Moloney murine leukemia viruses indicating that the degree of reverse transcriptase inhibition seen at drug concentrations lower than 2,000 FM is not sufficient to prevent virus infection of NIH 3T3 cells.
The work presented here demonstrates that inhibitors of retrovirus infection can be readily studied by using recombinant viruses that encode reporter genes such as 3-galactosidase. Advantages of this type of system include (i) rapid the potential for biohazard (infectious progeny are not made). These favorable features make this system suitable for screening multiple compounds for antiretroviral activity, as demonstrated in our studies of d4T, ddl, ddC, and PFA (Fig. 3) . Cytotoxic effects of compounds can be readily 
